Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

AstraZeneca’s Farxiga fails to receive U.S. approval for type 1 diabetes

Written by: | no-reply@reuters.com | Dated: Monday, July 15th, 2019

 

AstraZeneca’s Farxiga fails to get U.S. approval for Type-1 diabetes

 

(Reuters) – British drugmaker AstraZeneca Plc said on Monday the U.S. Food and Drug Administration declined to approve its diabetes treatment, Farxiga, for use as a supplement to insulin in adults with a rare type of the condition.

The company said the regulator issued a complete response letter, declining its application for using the drug in patients with Type-1 diabetes where insulin alone has not been able to control blood sugar levels.

Farxiga is already approved in the United States for use in Type-2 diabetes.

 

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun Koyyur)

 

Reuters source:

https://www.reuters.com/article/astrazenecas-farxiga-fails-to-get-fda-ap/astrazenecas-farxiga-fails-to-get-fda-approval-for-type-1-diabetes-idUSL4N24G19U

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom